Freestyle Navigator Continuous Glucose Monitoring System
Brief Summary:
To demonstrate that in patients with persistent poorly controlled diabetes, short/intermittent use of continuous glucose monitoring can driver better longer-term glycaemic control and HbA1c.
| Condition or disease | Intervention/treatment | Phase |
|---|---|---|
| Diabetes Mellitus | Device: FreeStyle Navigator Continuous Glucose Monitoring System | Not Applicable |
Detailed Description:
Study Overview This is a multi-centre pilot study across 6 study sites, recruiting 50 subjects. Each subject will use a FreeStyle Navigator Continuous Glucose Monitor for a period of 20 days at the start of the study, after which their Healthcare Professionals (HCPs) may recommend changes to their glucose management based on the continuous glucose monitoring(CGM) data. Subjects will then return to self-managing their diabetes with a blood glucose meter. After 2 months, subjects will use the FreeStyle Navigator for a further 5 days and review their results and glucose management with their HCPs. Subjects will again return to self-managing their diabetes with a blood glucose meter until the end of the study, when the last FreeStyle Navigator 5 day wear is completed and HbA1c and measures of glycaemic variability are recorded.
| Study Type : | Interventional (Clinical Trial) |
| Actual Enrollment : | 32 participants |
| Allocation: | N/A |
| Intervention Model: | Single Group Assignment |
| Masking: | None (Open Label) |
| Primary Purpose: | Treatment |
| Official Title: | Use of the FreeStyle Navigator Continuous Glucose Monitoring System to Enhance Education and Glycaemic Control |
| Study Start Date : | November 2010 |
| Actual Primary Completion Date : | February 2012 |
| Actual Study Completion Date : | June 2012 |
Resource links provided by the National Library of Medicine 
Intervention Details:
- Device: FreeStyle Navigator Continuous Glucose Monitoring System
Six x 5 day wears of the continuous glucose monitoring device. Two of the 6 wears will be using a masked device (1 at the start and 1 at the end of the study).
Primary Outcome Measures :
- Change in HbA1C From Baseline to 6 Months [ Time Frame: Baseline and 6 months ]
HbA1c at baseline HbA1c at 6 months Change in HbA1c(%)(6 months - baseline)
Secondary Outcome Measures :
- Number of Subjects Who Had Reduction in HbA1c of > or = 0.5% [ Time Frame: Baseline and 6 months ]
Number of subjects with a HbA1c reduction greater than or equal to 0.5% and 95% confidence interval from visit 1 (baseline) to visit 7 (6 months).
- Proportion of Time in Hypoglycaemia (<3.9 mmol/L)- Masked [ Time Frame: Baseline & 6 months ]
Proportion of time (hours per day) in hypoglycaemia (<3.9 mmol/L) for the masked phase. There were two masked phases in the study, one 5 day wear at baseline and one 5 day wear at 6 months. During masked wear subject were not able to see continuous glucose data from the device.
- Proportion of Time in Hypoglycaemia (<3.9mmol/L)-Unmasked [ Time Frame: 2 weeks following baseline & 3 months ]
Proportion of time (hours per day) in hypoglycaemia (<3.9mmol/L) for the unmasked phase
Information from the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
| Ages Eligible for Study: | 18 Years to 65 Years (Adult, Older Adult) |
| Sexes Eligible for Study: | All |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
- Subject with Type 1 or Type 2 diabetes requiring Multiple Daily Injections (MDI) (for >1yr)
- Age 18-65 years
- HbA1c above 8.0% for previous 2 HbA1c tests; the last HbA1c result being obtained within 3 months prior to enrolment
- Completed a structured education programme meeting NICE criteria between 6 to 24 months prior to enrolment.
- Testing Blood Glucose ≥ 4 times a day for previous 12 months
Exclusion Criteria:
- Subject is currently on an insulin pump.
- Subject has known allergy to medical grade adhesives
- Subject has concomitant disease that influences metabolic control
- Subject is participating in another study of a glucose monitoring device / drug that could affect glucose measurements / management
- Subject is currently using another continuous glucose monitoring device or has previously used real-time continuous glucose monitoring.
- Subject is receiving peritoneal dialysis solutions containing icodextrin
- Subject is pregnant / planning to become pregnant during study
Information from the National Library of Medicine
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01214824
| United Kingdom | |
| Ayr Hospital | |
| Ayr, Ayrshire, United Kingdom, KA6 6DX | |
| The Royal Liverpool University Hospital | |
| Liverpool, Cheshire, United Kingdom, L7 8XP | |
| University Hospital Aintree | |
| Liverpool, Cheshire, United Kingdom, L9 7AL | |
| Glan Clywd Hospital | |
| Rhyl, Denbighshire, United Kingdom, LL18 5UJ | |
| St. John's Hospital | |
| Livingston, Edinburgh, United Kingdom, EH54 6PP | |
Abbott Diabetes Care
Liverpool University Hospitals NHS Foundation Trust
National Heatlh Service Ayrshire and Arran
NHS Lothian
National Health Service, United Kingdom
Cardiff and Vale University Health Board
| Principal Investigator: | Jiten Vora, MRCP | The Royal Liverpool and Broadgreen University Hospitals NHS Trust |
| Responsible Party: | Abbott Diabetes Care |
| ClinicalTrials.gov Identifier: | NCT01214824 |
| Other Study ID Numbers: | ADC-PMR-NAV-09005 |
| First Posted: | October 5, 2010 Key Record Dates |
| Results First Posted: | June 6, 2013 |
| Last Update Posted: | July 2, 2013 |
| Last Verified: | June 2013 |
Keywords provided by Abbott Diabetes Care:
| Diabetes Continuous Glucose Monitoring |
Source: https://clinicaltrials.gov/ct2/show/NCT01214824
0 Response to "Freestyle Navigator Continuous Glucose Monitoring System"
Postar um comentário